These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18379783)

  • 1. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
    Lai R; Dang CT; Malkin MG; Abrey LE
    Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
    Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
    Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S; Rimondini S; De Angelis V; Colozza M; Bisagni G; Moretti G; Sidoni A; Basurto C; Aristei C; Anastasi P; Crinò L
    Oncologist; 2007 Jul; 12(7):766-73. PubMed ID: 17673608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
    Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B
    J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R; Szczylik C
    Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
    Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
    Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
    Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
    Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
    Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
    Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC; Holmes E; de Azambuja E; Metzger-Filho O; Hogge L; Scullion M; Láng I; Wardley A; Lichinitser M; Sanchez RI; Müller V; Dodwell D; Gelber RD; Piccart-Gebhart MJ; Cameron D
    Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
    Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
    Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.